Results 271 to 280 of about 47,543 (305)
Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab. [PDF]
Transl Lung Cancer ResTokito T +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Concurrent Chemoradiotherapy for Oropharyngeal Carcinoma
American Journal of Clinical Oncology: Cancer Clinical Trials, 2001The clinical results of definitive chemoradiotherapy for oropharyngeal carcinoma were retrospectively analyzed. Thirty-one patients with oropharyngeal carcinoma who received definitive radiation therapy between January 1986 and June 1998 were analyzed. The median age was 61 years. All patients had squamous cell carcinoma.
M, Kokubo +7 more
openaire +2 more sources
Otolaryngology–Head and Neck Surgery, 2017
ObjectiveThis study aimed to compare survival and toxicity between induction chemotherapy followed by concurrent chemoradiotherapy (IC + CCRT) and concurrent chemoradiotherapy (CCRT) alone in elderly patients with advanced nasopharyngeal carcinoma (NPC).Study DesignPropensity‐matched analysis of survival and toxicity in a retrospective elderly cohort ...
Chunlin, Wang +4 more
openaire +2 more sources
ObjectiveThis study aimed to compare survival and toxicity between induction chemotherapy followed by concurrent chemoradiotherapy (IC + CCRT) and concurrent chemoradiotherapy (CCRT) alone in elderly patients with advanced nasopharyngeal carcinoma (NPC).Study DesignPropensity‐matched analysis of survival and toxicity in a retrospective elderly cohort ...
Chunlin, Wang +4 more
openaire +2 more sources
Patients survey after concurrent chemoradiotherapy
Toukeibu Gan, 2010頭頸部癌に対し，化学放射線同時併用療法が広く行われるようになってきている。機能・器官・形態の温存の面から，手術的治療よりも患者のQOLを保つことが出来ると考えられているが，最近では治療後の合併症で日常生活に支障をきたし，必ずしも手術療法より患者のQOLが保たれているとはいいがたい面もある。実際に治療後の患者がQOLを保つことができているかを検討するために，当科で化学放射線同時併用療法を受けた頭頸部癌患者に対し，その後の合併症，治療中の問題点，改善点，満足度などについてアンケート調査を行ったので報告する。結果として一番問題となる症状は口渇であったが，経過観察期間が長くなるにつれて症状は改善傾向にあった。満足度に関しては「満足」，「ほぼ満足」が9割を超えており ...
Toshikazu Shimane +7 more
openaire +1 more source
Adjuvant concurrent chemoradiotherapy in extrahepatic cholangiocarcinoma.
Journal of Clinical Oncology, 20204583 Background: Resected cholangiocarcinomas are rare and have high relapse rates. Adjuvant chemotherapy is the standard of care (BiLCAP Trial). Adjuvant radiation therapy benefit is not well defined. This study aims to evaluate survival outcomes of the effect of adjuvant chemoradiotherapy compared to chemotherapy in extrahepatic cholangiocarcinoma (
Walid Labib Shaib +9 more
openaire +1 more source
Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma
International Journal of Radiation Oncology*Biology*Physics, 2004To analyze the results of concurrent chemoradiotherapy in patients with locoregional recurrent nasopharyngeal carcinoma.We performed a retrospective analysis of 35 patients with locoregional recurrent nasopharyngeal carcinoma referred to our department between March 1994 and November 2002.
Donald, Poon +9 more
openaire +2 more sources
X-ray-responsive polypeptide nanogel for concurrent chemoradiotherapy
Journal of Controlled Release, 2021Concurrent chemoradiotherapy (CCRT) is a standard treatment regimen for medically inoperable stage III non-small-cell lung carcinoma (NSCLC) owing to its superior prognostics compared with the sequential modality. Nevertheless, the current pattern of CCRT still fails to provide satisfactory survival outcome. Furthermore, CCRT is always accompanied by a
Juan, Wang +8 more
openaire +2 more sources